


Achaogen  
Investor Relations Department  
7000 Shoreline Court,  
3rd Floor  
South San Francisco, CA 94080  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#) 

**NASDAQ: AKAO**


Last Trade:	19.93
Trade Time:	4:00 PM ET Jul 26, 2017
Change:	0.03  (0.151%)
Day Range	19.21 - 20.70
52-Week Range	3.55 - 27.79
Volume	921,766

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, or CRE. In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent a... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Jul 25, 2017

[Achaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant Infections](#)

Jul 24, 2017

[Achaogen Announces New Employment Inducement Grants](#)

Jul 13, 2017

[Achaogen Appoints Dr. Karen Bernstein to its Board of Directors](#)

Jun 22, 2017

[Achaogen Announces New Employment Inducement Grants](#)

Jun 5, 2017

[Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

Mar 14, 2017

[Annual Report \(10-K\)](#)

Apr 26, 2017

[Proxy Statement \(DEF 14A\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)

Aug 8, 2016

[Quarterly Report \(10-Q\)](#)